

Individualized treatment of severe cancers

Interim report January-March 2023

CHOSA Oncology AB (publ) | 559037-2271 | www.CHOSAoncology.se

01

Contents

Significant events	03
CEO letter	04
CHOSA Oncology AB	05
Commentary on the group's financial development for the first quarter of 2023	07
Financial reports - The Group	
Income statement in summary	08
Balance sheet in summary	09
Change of own capital	10
Cash flow analysis in summary	11
Financial reports - Parent company	
Income statement in summary	12
Balance sheet in summary	13
Change of own capital	14
Cash flow analysis in summary	15
Company information	16

Summary of interim report

First quarter (2023-01-01 – 2023-03-31)

- The group's other operating income amounted to SEK 0 thousand (0).
- The group's result after financial items amounted to SEK -2,308 thousand (-17,191).
- The group's earnings per share amounted to SEK -0.037 (-0.75).
- The group's equity ratio amounted to 56% (67.2)

During the first quarter, the conditional reverse acquisition of CHOSA Oncology AB by RhoVac AB was carried out.

"CHIOSA Oncology AB (publ)" refers to CHOSA Oncology AB (publ) with organization number 559037-2271.

"Company" or "CHOSA" refers to the group, i.e. CHOSA Oncology AB (publ) and its wholly owned subsidiaries RhoVac ApS and CHOSA ApS.

Definitions:

- **Earnings per share before dilution:** Earnings for the period divided by the average number of outstanding shares in the period.
- **Earnings per share after dilution:** Earnings for the period divided by the average number of outstanding shares in the period and outstanding potential ordinary shares.
- **Equity ratio:** Equity divided by total capital.



Significant events

January 2023

11 Jan - Communiqué from the extraordinary general meeting of RhoVac AB

18 Jan - RhoVac AB has completed the acquisition of CHOSA ApS and a new board and managing director have taken office

March 2023

7 March - CHOSA Oncology AB presents at Stora Aktiedagarna in Stockholm

February 2023

10 Feb - RhoVac AB changes name to CHOSA Oncology AB

15 Feb - The CHOSA team will attend ASCO and present phase II data from the iCIP study

27 Feb - CHOSA Oncology (formerly RhoVac AB) publishes year-end report for the financial year 2022

Significant events after the end of the period

8 April - CHOSA Oncology AB initiates payment of the last part of the loan to RhoVac's lender

11 April - CHOSA Oncology AB's poster *Predictive biomarker for cisplatin in prospective phase 2 of liposomal cisplatin in metastatic breast cancer* accepted for ASCO's annual meeting

18 April - CHOSA Oncology AB's repayment of the convertible loan is ongoing

20 April - CHOSA Oncology AB's repayment of the convertible loan is ongoing - update

25 April - CHOSA Oncology AB calls for an annual general meeting

3 May - CHOSA Oncology AB announces approved re-listing memorandum.

CEO letter

Dear shareholders and stakeholders in CHOSA,

I want to thank RhoVac's shareholders for voting in favor of the conditional reverse acquisition with CHOSA earlier this year. We think this is a good decision as we believe the assets of CHOSA are likely to have significant impact for many patients and a beneficial investment case for shareholders.

The background for iCIP is the fact that cancer continues to be a very deadly disease with a significant medical need. For many of the largest cancer types even the best new products only work in as few as 25-30% of patients. Although we hear about all the successes with new cancer treatments, the fact remains that for most patients, a cure is out of reach. There are many cancer treatments - more than 300 approved products, but as mentioned, the results are often disappointing. The problem is that cancer is personal, and all tumors are unique.

iCIP™ is a combination of two intelligent solutions: LiPlaCis® and its Drug Response Predictor (DRP®) gene test. The science behind LiPlaCis is that a lipid bubble - carrying cisplatin - opens directly at the tumor site and potentially increases the effect and apparently decreases the side effects for the patients. The Drug Response predictor (DRP®), which is a companion diagnostic tool, has demonstrated that it can clearly differentiate between patients that benefit - and therefore should receive LiPlaCis, and those who do not - and therefore should receive a different treatment.

The CHOSA Oncology team has extensive experience in the pharmaceutical industry with two anti-cancer products previously approved by the US FDA - products that are now available for treatment of cancer patients - as well as several trade sales on their CVs.

CHOSA aim for approval of iCIP in several cancer indications. However, the first to market strategy is breast cancer where we have strong clinical phase 2b results. These data form the basis of an abstract that has been approved for

presentation at the ASCO conference in June. Secondly, we have a focus on lung cancer, where we already have published study results that show that our gene test can identify the patients who will benefit from our treatment. During the first quarter we obtained approval of the abstract for ASCO, and we have participated in several conferences and met with investors. Further the period has been characterized by administrative work for the re-listing process which is coming to a positive resolution to move from the observation list to the regular one.

During the last quarter of 2022, the final reporting of the EU grant that RhoVac received in 2019 from the European Commission's innovation fund began. A protracted process which in turn became the starting point for the repayment of the convertible loan which was also terminated after the end of the period. We thank all loan givers for the patience during the process!

CHOSA Oncology is now in dialogues with pharmaceutical companies believed to have an interest in acquiring the iCIP™ program through a partnership or outright acquisition. In parallel with the sales activities, the company will also create value by determining the path to approval with the regulatory authorities, and by preparing as far as possible for the next clinical study including the scale-up process of LiPlaCis for commercial use.

Since iCIP has succeeded in demonstrating efficacy from a clinical phase 2b results, CHOSA has reached a very important milestone, where many other projects have previously failed. We take this with us for the continued development of the company and the project, and hope that existing and future shareholders want to join us on our journey ahead to provide effective precision medicine to patients!

Peter Buhl Jensen
CEO, CHOSA Oncology AB

”

”Since iCIP has succeeded in demonstrating efficacy in a clinical phase 2b results, CHOSA has reached a very important milestone, where many other projects have previously failed.”

Peter Buhl Jensen
CEO, CHOSA Oncology AB



CHOSA Oncology AB

The iCIP concept that CHOSA has developed consists partly of LiPlaCis, which is a liposomal formulation that distributes chemotherapy (specifically cisplatin) locally to the tumor, and partly of DRP® (Drug Response Predictor), which is a diagnostic tool that predicts whether the treatment with cisplatin will be successful - or not.

DRP® is a predictive analytics technology that aims to improve the effectiveness of cancer treatment by providing the physician with valuable data on how likely a patient is to benefit from cisplatin or not. The prediction of response is complex because there are more than 900 genes and proteins that influence cisplatin resistance. CHOSA's technology includes a patented algorithm that is based on the patient's tumor biopsy and analyzes the expression of the most significant genes, generating a score on the patient's likelihood of responding well to cisplatin treatment. The score enables the doctor to more easily choose to give cisplatin treatment.

By using DRP® to identify in advance, the patients who are likely to benefit from cisplatin treatment and then treat these patients with LiPlaCis®, the patients can have better treatment effect and fewer side effects than other alternatives. In November 2022, CHOSA received phase 2b data for iCIP™ against metastatic breast cancer, showing that patients selected by DRP® responded better to treatment, had longer progression-free survival, and perhaps even longer overall survival than those patients identified as unlikely to respond to treatment. Another major advantage of iCIP™ is that it appears to have a better toxicity profile, which opens up a great opportunity for the drug to be used in combination treatments - an increasingly common form of treatment in cancer treatment.

CHOSA's drug candidate LiPlaCis® is an improved formulation of the already approved and widely used chemotherapy cisplatin. LiPlaCis® uses a liposome formulation to encapsulate and transport cisplatin to the tumor. The liposome "bubble" is specifically designed to target secretory phospholipases (sPLA2s) - an enzyme overexpressed in tumors. Upon contact with the enzyme, the liposome breaks down and releases the encapsulated cisplatin directly on the tumor. LiPlaCis® has been shown *in-vivo* and in patients to preferentially target cancer cells over normal tissue, and therefore results in higher efficacy, safety and tolerability compared to conventional cisplatin treatment. Although liposomes are a common drug delivery platform, there are currently no other liposome formulations of cisplatin on the market.

LiPlaCis® is not indication-specific, which means that it has the potential to be used in several cancers. Previous studies with LiPlaCis® have shown some effect in patients with breast cancer, lung cancer, skin cancer, esophagus and throat cancer. Cisplatin is used in more than 16 different cancers. LiPlaCis® has the potential to be used for all of these. Observations from 100 patients who have participated in clinical trials with LiPlaCis® indicate that side effects such as neurotoxicity, nausea, which are often associated with cisplatin, do not occur during treatment with LiPlaCis®. The presumed milder toxicity profile is probably due to the liposome's bubble preventing cisplatin from reaching healthy tissue in the body. The absence of the common side effect profile could also make LiPlaCis® particularly desirable in the treatment of various types of childhood cancer, as oncologists with existing options are often forced to discontinue treatments. CHOSA also to create value by preparing the product for the upcoming registration-based study by determining the approval process with authorities, as well as to prepare for the production scale-up of LiPlaCis®.



Business model and strategy

CHOSA's strategy is to out-license or sell the iCIP program to pharmaceutical companies that can finance the next registration-founding study. The board intends to continuously evaluate how CHOSA can most effectively create value with a focus on out-licensing, sales or partnerships. In parallel with negotiations with potential partners and buyers, CHOSA will also create value by preparing the product for the upcoming clinical trial study by determining the approval process with authorities, as well as preparing for production scale-up of LiPlaCis®.

Broad development plan

- Regulatory meetings with FDA and EMA.
- Recruit CRO for the clinical trial, opinion leaders & clinicians for the clinical trial.
- Prepare for production scale-up of LiPlaCis®.
- Enter into iCIP partnership agreements.

Group relationship and shareholding

CHOSA Oncology AB (publ) is the parent company of a group that includes the wholly owned subsidiary RhoVac ApS and CHOSA ApS. In addition to the above, CHOSA has no additional shareholdings in other companies.

Business-related risks and uncertainty factors

The risks and uncertainty factors that CHOSA's operations are exposed to are, in summary, related to, among other things, drug development, competition, technology development, patents, authority requirements, capital needs, currencies and interest rates. For a more detailed account of risks and uncertainty factors, reference is made to the annual report for 2022, which is available on the Company's website.

The stock

The share in CHOSA Oncology AB (publ) (former RhoVac AB) was listed on the Spotlight Stock Market ("Spotlight") on March 9, 2016. Spotlight operates a trading platform (MTF) and is a special company name for ATS Finans AB, a securities company under the supervision of the Financial Supervisory Authority. ATS Finans AB is a subsidiary of Spotlight Group AB, which as of September 15, 2020 is listed on Spotlight. As of March 31, 2023, the number of shares in CHOSA amounted to 62,774,633. The company has a warrant program aimed at senior executives and key personnel in the RhoVac Group. In the warrant program a total of 1,000,000 warrants have been subscribed. The program constituted key resources in RhoVac.

RhoVac's acquisition of Chosa

The purchase price for all shares in CHOSA amounts to SEK 45,913,914 and was paid through promissory notes which are immediately set off against 43,727,531 newly issued shares in RhoVac at a subscription price of SEK 1.05 per share (the "Offset issue"). The subscription price of SEK 1.05 per share corresponds to a premium of approximately 75 percent based on the volume-weighted the average price of the company's share during 30

trading days before December 5, 2022. In the transaction, RhoVac was thus valued at approximately SEK 20 million.

Through the Issue, the number of shares in RhoVac increased by 43,727,531, from 19,047,102 to 62,774,633, and the share capital increased by SEK 7,870,955.58, from SEK 3,428,478.36 to SEK 11,299,433.94. After the transaction, the sellers jointly held approximately 69.7 percent of the shares and votes in the Company, and the current shareholders in CHOSA will thus jointly hold approximately 30.3 percent. The board considers that the applied valuation and the subscription price as a result of the valuation are market-based and fair based on negotiations with the Sellers. In addition, the board has obtained a so-called "fairness opinion" from Västra Hamnen Corporate Finance AB, which supports that the proposed exchange ratio is fair from a financial perspective for the shareholders in RhoVac.

In addition to the approval from the extraordinary general meeting on January 11, 2023, the execution of the transaction was also conditional on the investment in CHOSA, described above, being completed.

Extraordinary general meeting

RhoVac's acquisition of CHOSA was subject to approval by the extraordinary general meeting on January 11, 2023. The proposed items on the agenda for the extraordinary general meeting included decisions on, among other things, approval of the transaction, amendment of the company's articles of association to enable the offsetting issue and change of the company's name, the offsetting issue and election of a new board. M2 Asset Management AB, the largest shareholder holding approximately 20.4 percent of the total number of shares and votes in RhoVac, undertook to vote for the transaction and related decisions at the extraordinary general meeting. The notice to the extraordinary general meeting was published in a separate press release. Before that extraordinary general meeting, RhoVac published a teaser describing CHOSA and the merged entity.

Lock-up agreement

In connection with the transaction, all Sellers and M2 Asset Management AB, with customary exceptions, have undertaken not to sell shares in CHOSA for a period of 6 months after the completion of the transaction.

Application for continued listing on Spotlight

On May 3, Spotlight approved the relisting memorandum, and the share is traded on the regular list. The approval of the relisting memorandum means that Spotlight has confirmed that CHOSA Oncology is considered to meet all current listing requirements.

List of owners

For CHOSA's list of owners, refer to Spotlight via the following link:

 <https://spotlightstockmarket.com/sv/bolag/irabout?InstrumentId=XSAT01001554>

Principles for the preparation of the interim report

This interim report has been prepared in accordance with the Annual Accounts Act and the Accounting Act's general advice BFNAR 2012:1 "K3".

Review by auditor

The interim report has not been subject to review by the Company's auditor.

Upcoming financial reports

CHOSA prepares and publishes a financial report every quarter.

Upcoming reports are scheduled as follows:

- **Half-year report** 2023-08-28
- **Interim report 3** 2023-11-10
- **Year-end report** 2024-02-09

Submission of quarterly report 1

Lund, 5 May 2023

CHOSA Oncology AB (publ)

The board



For further information

Peter Buhl, CEO,

Email: pbj@buhloncology.com,

Phone: + 45 21 60 89 22

Commentary on the group's financial development for the first quarter of 2023

Turnover and results

The group's other operating income for the quarter amounted to SEK 0 thousand (3,484). The result for the first quarter of 2023 in the group amounted to SEK -2,308 thousand (-14,263).

Liquidity and balance sheet

The group's cash and cash equivalents as of March 31, 2023 amounted to SEK 17,548 thousand (13,688). In addition to the group's cash and cash equivalents, the group has prepaid expenses and accrued income of SEK 119 thousand (15,821), as well as tax receivables of SEK 7,951 thousand (10,534). In that case expenses for research and development arise in the Danish subsidiary, a tax credit can be obtained, according to The "tax credit scheme" in Denmark. According to this, RhoVac ApS will receive current tax revenue for part of the expenses attributable to research and development. RhoVac's credit under the "Tax credit scheme" for 2022 will be paid in November 2023. Supplier debts amounted to SEK 393 thousand (818). Equity amounts to SEK 23,486 thousand (27,887) out of a total balance sheet total of SEK 41,953 thousand (41,506).

Solidity

The group's equity ratio as of 31 March 2023 amounted to 56.0% (67.2).

The parent company

The parent company's has had no revenue for the first quarter of 2023 (SEK 510 thousand). The result for the first quarter of 2023 amounted to SEK -1,357 thousand (-2,487).

Income statement in summary

(TSEK)

	2023-01-01 -2023-03-31	2022-01-01 -2022-03-31	2022-01-01 -2022-12-31
Operating income			
Other operating income	0	0	4 085
Operating costs			
Other external costs	-2 087	-15 094	-39 193
Personnel costs	-109	-2 120	-6 233
Other operating costs	-4	-43	22
Operating results	-2 200	-17 258	-41 319
Results from financial items			
Other interest income and similar income	266	67	1 525
Interest expenses and similar expenses	-374	0	-1 474
Results after financial items	-2 308	-17 191	-41 268
Tax on the year's profit	0	2 928	7 860
RESULTS FOR THE YEAR/PERIOD	-2 308	-14 263	-33 408

Balance sheet in summary

(TSEK)

	2023-03-31	2022-03-31	2022-12-31
ASSETS			
Fixed assets			
Intangible fixed assets			
Patents	10 634	0	0
Total fixed assets	10 634	0	0
Current assets			
Receivables			
Current tax assets	7 951	10 534	8 231
Other claims	5 701	1 463	2 279
Prepayments and accrued income	119	15 821	4 472
Total current receivables	13 771	27 818	14 982
Cash and bank balances	17 548	13 688	15 122
Total current assets	31 319	41 506	30 104
TOTAL ASSETS	41 953	41 506	30 104

(TSEK)

	2023-03-31	2022-03-31	2022-12-31
EQUITY AND LIABILITIES			
Equity capital			
Share capital (62,774,633 shares)	11 299	3 428	3 428
Other contributed capital	252 201	211 293	211 293
Other equity including profit for the year	-240 014	-186 835	-205 329
Equity attributable to the parent company's shareholders	23 486	27 887	9 392
Total equity	23 486	27 887	9 392
Current liabilities			
Accounts payable	393	818	1 010
Other current liabilities	15 159	485	16 735
Accrued costs and prepaid income	2 915	12 317	2 967
Total short-term liabilities	18 467	13 619	20 712
TOTAL EQUITY AND LIABILITIES	41 953	41 506	30 104

Change of own capital (TSEK)

	Share capital	Other added capital	Other equity including profit for the year	Total equity attributable to the parent company's shareholders	Total equity capital
Opening balance as of 1 January 2023	3 428	211 293	-205 677	9 043	9 043
This year's results			-2 308	-2 308	-2 308
<i>Changes in reported values of assets and liabilities:</i>					
Translation differences				0	0
Total changes in value	0	0	0	0	0
<i>Transactions with owners:</i>					
Rights issue	7 871	37 129	-28 256	16 744	16 744
Subscription options				0	0
Total transactions with shareholders	7 871	37 129	-28 256	16 744	16 744
Closing balance as of 31 March 2023	11 299	248 422	-236 241	23 479	23 479

Opening balance as of 1 January 2022	3 428	211 293	-173 025	41 696	41 696
This year's results			-14 263	-14 263	-14 263
<i>Changes in reported values of assets and liabilities:</i>					
Translation differences			454	454	454
Total changes in value	0	0	454	454	454
<i>Transactions with owners:</i>					
Rights issue					
Subscription options				0	0
Total transactions with shareholders	0	0	0	0	0
Closing balance as of 31 March 2022	3 428	211 293	-186 834	27 886	27 886

Opening balance as of 1 January 2022	3 428	211 293	-173 025	41 696	41 696
This year's results			-33 752	-33 752	-33 752
<i>Changes in reported values of assets and liabilities:</i>					
Translation differences			1 100	1 100	1 100
Total changes in value	0	0	1 100	1 100	1 100
<i>Transactions with owners:</i>					
Rights issue					
Subscription options				0	0
Total transactions with shareholders	0	0	0	0	0
Closing balance as of 31 December 2022	3 428	211 293	-205 677	9 043	9 043

Cash flow analysis in summary

(TSEK)

	2023-01-01 -2023-03-31	2022-01-01 -2022-03-31	2022-01-01 -2022-12-31
The ongoing operations			
Operating results	-2 200	-17 258	-41 319
Adjustments for items not included in the cash flow:	188	0	0
Interest received	11	0	0
Interest paid	-4	-25	-57
Paid income tax	0	0	8 112
Cash flow from current operations before changes in working capital	-2 005	-17 283	-33 264
Cash flow from changes in working capital			
Decrease(+)/increase(-) in other short-term receivables	4 398	1 574	13 257
Decrease(-)/increase(+) in accounts payable	-903	-5 722	-5 647
Decrease(-)/increase(+) in other short-term liabilities	-132	5 067	-5 254
Cash flow from current operations	1 358	-16 364	-30 908
Investment activities			
Acquisition of subsidiaries	909	0	0
Cash flow from financing activities	909		
Financing activities			
Convertible loans	0	0	14 980
Cash flow from financing activities	0	0	14 980
The year's cash flow	2 267	-16 364	-15 928
Cash and cash equivalents at the beginning of the year/period	15 121	29 621	29 621
Exchange rate differences in cash and cash equivalents	160	430	1 429
Cash and cash equivalents at the end of the year/period	17 548	13 688	15 122

Income statement in summary

(TSEK)

	2023-01-01 -2023-03-31	2022-01-01 -2022-03-31	2022-01-01 -2022-12-31
Operating income			
Net sales	0	510	1977
Operating costs			
Other external costs	-877	-1 631	-6 203
Personnel costs	-107	-1 353	-4 112
Other operating costs	-4	-13	-6
Operating results	-988	-2 487	-8 344
Results from financial items			
Results from shares in group companies	0		-156 359
Other interest income and similar income	0		1 355
Interest expenses and similar expenses	-369		-1 450
Profit after financial items	-1 357	-2 487	-164 798
Profit before tax	-1 357	-2 487	-164 798
Tax on the year's profit	0	0	0
RESULTS FOR THE YEAR/PERIOD	-1 357	-2 487	-164 798

Balance sheet in summary

(TSEK)

	2023-03-31	2022-03-31	2022-12-31
ASSETS			
Fixed assets			
Financial fixed assets			
Shares in group companies	45 900	156 359	0
Receivables from group companies	21 960	10 122	21 960
	67 860	166 481	21 960
Total fixed assets	67 860	166 481	21 960
Current assets			
Receivables			
Other claims	428	453	620
Prepayments and accrued income	119	358	105
Total current receivables	547	811	725
Cash and bank balances	1 594	4 665	3 160
Total current assets	2 141	5 476	3 885
TOTAL ASSETS	70 001	171 957	25 845

(TSEK)

	2023-03-31	2022-03-31	2022-12-31
EQUITY AND LIABILITIES			
Equity capital			
Restricted equity			
Share capital	11 299	3 428	3 428
	11 299	3 428	3 428
Free equity			
Share premium fund	249 196	211 167	211 167
Balanced profit or loss	-206 887	-42 727	-42 727
Result for the year/period	-1 356	-2 486	-164 798
	40 953	165 954	3 643
Total equity	52 252	169 382	7 071
Current liabilities			
Accounts payable	105	360	581
Other current liabilities	14 994	153	15 228
Accrued costs and prepaid income	2 650	2 062	2 965
Total short-term liabilities	17 749	2 575	18 774
TOTAL EQUITY AND LIABILITIES	70 001	171 957	25 845

Change of own capital (TSEK)

	Share capital	premium fund	balanced win or loss	The year's results	total equity
Opening balance as of 1 January 2023	3 428	211 293	-42 727	-164 160	7 834
Disposition of the previous year's results			-164 160	164 160	0
The period's results				-1 357	-1 357
Transactions with owners:					
Rights issue					
Subscription options					
Total transactions with shareholders	0	0	0	0	0
Closing balance as of 31 March 2023	3 428	211 293	-206 887	-1 357	6 477

Opening balance as of 1 January 2022	3 428	211 167	-34 365	-8 362	171 869
Disposition of the previous year's results			-8 362	8 362	0
The period's results				-2 486	-2 486
Transactions with owners:					
Rights issue					
Subscription options					0
Total transactions with shareholders	0	0	0	0	0
Closing balance as of 31 March 2022	3 428	211 167	-42 727	-2 486	169 383

Opening balance as of 1 January 2022	3 428	211 167	-34 365	-8 362	171 869
Disposition of the previous year's results			-8 362	8 362	0
The period's results				-164 160	-164 160
Transactions with owners:					
Rights issue					
Subscription options					0
Total transactions with shareholders	0	0	0	0	0
Closing balance as of 31 December 2022	3 428	211 167	-42 727	-164 160	7 709

Cash flow analysis in summary

(TSEK)

	2023-01-01 -2023-03-31	2022-01-01 -2022-03-31	2022-01-01 -2022-12-31
The ongoing operations			
Operating results	-987	-2 486	-8 344
Adjustments for items not included in the cash flow:	0	0	0
Interest received	0	0	0
Interest paid	0	0	-1
Cash flow from current operations before changes in working capital	-987	-2 486	-8 345
Cash flow from changes in working capital			
Decrease(+)/increase(-) in other short-term receivables	179	-51	34
Decrease(-)/increase(+) in accounts payable	-476	159	380
Decrease(-)/increase(+) in other short-term liabilities	-281	176	-273
Cash flow from current operations	-1 565	-2 202	-8 204
Investment activities			
Acquisition of subsidiaries	0	0	-10 483
Cash flow from financing activities	0	0	-10 483
Financing activities			
Convertible loans	0	0	14 980
Cash flow from financing activities	0	0	14 980
The year's cash flow	-1 565	-2 202	-3 707
Cash and cash equivalents at the beginning of the year/period	3 160	6 867	6 867
Cash and cash equivalents at the end of the year/period	1 595	4 665	3 160

Company information

CHOSA Oncology AB – parent company

Company name	CHOSA Oncology AB
Trade name	"CHOSA". Shares are subject to trading on Spotlight.
ISIN-codes	The Shares ISIN code is: SE0007784319.
Seat and domicile	Lund, Sweden
Organization number	559037-2271
Date of incorporation	2023-01-11
Date when the company started its operation	2015-11-25
Country	Sweden
Legal form	Public limited company
Legislation	Swedish law and the Swedish Limited Liability Companies Act
Address	Scheeleorget 1, 223 81 Lund, Sweden
Phone	+46 73-751 72 78
Website	www.CHOSAoncology.com
Auditor	Deloitte AB (Box 233, 391 22 Kalmar), chief accountant Magnus Andersson
LEI-code	5493002SFL9YXB0A0027

RhoVac ApS – affiliated company

Country	Denmark
Country from where the subsidiary operates	Denmark
Organization number	31159008
Ownership share	100 percent

CHOSA Oncology ApS – affiliated company

Country	Denmark
Country from where the subsidiary operates	Denmark
Organization number	43134477
Ownership share	100 percent



CHOSA
INTELLIGENT ONCOLOGY

Medicon Village AB
Scheeletorget 1
223 81 Lund, Sweden

www.CHOSAoncology.se



Q1